Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Actinium Pharmaceuticals, Inc. ATNM

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$90,000
$-33.9M
$-24.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 90,000.00
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.1 · Net income -33.9
-20M-40M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -40274.4%
-20000%-40000%-60000%
200720162025
ROE
FY2025 · ROE -167.0%
-200%-400%-600%
200720162025
Three returns, three denominators.

Each USD of equity lost 167 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -24.7
3M6M-20M-40M
200720162025

Total assetsUSD 51.8M
EquityUSD 7.8M
CashUSD 48.0M
Current ratio6.20×

Equity funds 15% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ATNM, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.0◌0.00.00.0◌◌◌◌◌◌◌◌◌0.00.0◌◌◌
Operating income $B−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌0.0−0.0◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌
EPS, diluted $−1.09−1.27−1.83−1.37−1.20−1.83−4.40−0.22−0.40−0.50−0.55−0.90−0.47−7.58−4.300.01◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−167.0−110.6−94.9−47.2−36.7−66.4−303.0−210.4−167.9−121.7———−782.3−495.3−75.1−136.9−146.2−162.4
Shares out B0.030.030.030.030.020.020.160.120.080.060.040.030.020.020.010.01◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image